Galiellalactone is a direct inhibitor of the transcription factor STAT3 in prostate cancer cells

Journal of Biological Chemistry

Volumn 289, Issue 23, 2014, Pages 15969-15978

  Don Doncow, Nicholas ^a   Escobar, Zilma ^a   Johansson, Martin ^a   Kjellström, Sven ^a   Garcia, Victor ^b   Munoz, Eduardo ^b   Sterner, Olov ^a   Bjartell, Anders ^a   Hellsten, Rebecka ^a  

^a LUND UNIVERSITY   (Sweden)

^b UNIVERSITY OF CÓRDOBA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACIDS; BIOSYNTHESIS; CELL DEATH; DISEASES; MASS SPECTROMETRY; PHOSPHORYLATION; RECOMBINANT PROTEINS; STEM CELLS;

CONSTITUTIVELY ACTIVES; MASS SPECTROMETRY ANALYSIS; MOLECULAR MECHANISM; PHARMACOLOGICAL METHODS; PROSTATE CANCER CELLS; REACTIVE INHIBITORS; SIGNALING INHIBITORS; THERAPEUTIC TARGETS;

CELL SIGNALING;

ANTINEOPLASTIC AGENT; CYSTEINE; GALIELLALACTONE; SEPHAROSE; STAT3 PROTEIN; STREPTAVIDIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BIOTINYLATION; CANCER CELL LINE; CANCER INHIBITION; CANCER STEM CELL; CONFOCAL MICROSCOPY; CONTROLLED STUDY; COVALENT BOND; DRUG PROTEIN BINDING; DRUG STRUCTURE; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MASS SPECTROMETRY; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DNA BINDING; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION;

ANTICANCER DRUG; CANCER THERAPY; PROSTATE CANCER; SMALL MOLECULE; STAT3;

AMINO ACID SEQUENCE; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; LACTONES; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MASS SPECTROMETRY; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PROSTATIC NEOPLASMS; PROTEIN BINDING; STAT3 TRANSCRIPTION FACTOR;

EID: 84902169125     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M114.564252     Document Type: Article

References (36)

1. Calò, V., Migliavacca, M., Bazan, V., Macaluso, M., Buscemi, M., Gebbia, N., and Russo, A. (2003) STAT proteins: from normal control of cellular events to tumorigenesis. J. Cell Physiol. 197, 157-168
2. Barré, B., Vigneron, A., Perkins, N., Roninson, I. B., Gamelin, E., and Coqueret, O. (2007) The STAT3 oncogene as a predictive marker of drug resistance. Trends Mol. Med. 13, 4-11
3. Peyser, N. D., and Grandis, J. R. (2013) Critical analysis of the potential for targeting STAT3 in human malignancy. Onco. Targets Ther. 6, 999-1010
4. Sellier, H., Rébillard, A., Guette, C., Barré, B., and Coqueret, O. (2013) How should we define STAT3 as an oncogene and as a potential target for therapy? JAKSTAT 2, e24716
5. Quintás-Cardama, A., and Verstovsek, S. (2013) Molecular pathways: Jak/STAT pathway: mutations, inhibitors, and resistance. Clin. Cancer Res. 19, 1933-1940
6. Sansone, P., and Bromberg, J. (2012) Targeting the interleukin-6/Jak/stat pathway in human malignancies. J. Clin. Oncol. 30, 1005-1014
7. Koskela, H. L., Eldfors, S., Ellonen, P., van Adrichem, A. J., Kuusanmäki, H., Andersson, E. I., Lagström, S., Clemente, M. J., Olson, T., Jalkanen, S. E., Majumder, M. M., Almusa, H., Edgren, H., Lepistö, M., Mattila, P., Guinta, K., Koistinen, P., Kuittinen, T., Penttinen, K., Parsons, A., Knowles, J., Saarela, J., Wennerberg, K., Kallioniemi, O., Porkka, K., Loughran, T. P., Jr., Heckman, C. A., Maciejewski, J. P., and Mustjoki, S. (2012) Somatic STAT3 mutations in large granular lymphocytic leukemia. N. Engl. J. Med. 366, 1905-1913
8. Pilati, C., Amessou, M., Bihl, M. P., Balabaud, C., Nhieu, J. T., Paradis, V., Nault, J. C., Izard, T., Bioulac-Sage, P., Couchy, G., Poussin, K., and Zucman-Rossi, J. (2011) Somatic mutations activating STAT3 in human inflammatory hepatocellular adenomas. J. Exp. Med. 208, 1359-1366
9. Ferlay, J., Shin, H. R., Bray, F., Forman, D., Mathers, C., and Parkin, D. M. (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN. Int. J. Cancer 127, 2893-2917
10. Mohler, J. L., Armstrong, A. J., Bahnson, R. R., Boston, B., Busby, J. E., D'Amico, A. V., Eastham, J. A., Enke, C. A., Farrington, T., Higano, C. S., Horwitz, E. M., Kantoff, P. W., Kawachi, M. H., Kuettel, M., Lee, R. J., MacVicar, G. R., Malcolm, A. W., Miller, D., Plimack, E. R., Pow-Sang, J. M., Roach, M., 3rd., Rohren, E., Rosenfeld, S., Srinivas, S., Strope, S. A., Tward, J., Twardowski, P., Walsh, P. C., Ho, M., and Shead, D. A. (2012) Prostate cancer, Version 3.2012: featured updates to the NCCN guidelines. J. Natl. Compr. Canc. Netw. 10, 1081-1087
11. Sridhar, S. S., Freedland, S. J., Gleave, M. E., Higano, C., Mulders, P., Parker, C., Sartor, O., and Saad, F. (2014) Castration-resistant prostate cancer: from new pathophysiology to new treatment. Eur. Urol. 65, 289-299
12. Horinaga, M., Okita, H., Nakashima, J., Kanao, K., Sakamoto, M., and Murai, M. (2005) Clinical and pathologic significance of activation of signal transducer and activator of transcription 3 in prostate cancer. Urology 66, 671-675
13. Mora, L. B., Buettner, R., Seigne, J., Diaz, J., Ahmad, N., Garcia, R., Bowman, T., Falcone, R., Fairclough, R., Cantor, A., Muro-Cacho, C., Livingston, S., Karras, J., Pow-Sang, J., and Jove, R. (2002) Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. Cancer Res. 62, 6659-6666
14. Tam, L., McGlynn, L. M., Traynor, P., Mukherjee, R., Bartlett, J. M., and Edwards, J. (2007) Expression levels of the JAK/STAT pathway in the transition from hormone-sensitive to hormone-refractory prostate cancer. Br. J. Cancer 97, 378-383
15. Abdulghani, J., Gu, L., Dagvadorj, A., Lutz, J., Leiby, B., Bonuccelli, G., Lisanti, M. P., Zellweger, T., Alanen, K., Mirtti, T., Visakorpi, T., Bubendorf, L., and Nevalainen, M. T. (2008) Stat3 promotes metastatic progression of prostate cancer. Am. J. Pathol. 172, 1717-1728
16. Kroon, P., Berry, P. A., Stower, M. J., Rodrigues, G., Mann, V. M., Simms, M., Bhasin, D., Chettiar, S., Li, C., Li, P. K., Maitland, N. J., and Collins, A. T. (2013) JAK-STAT blockade inhibits tumor initiation and clonogenic recovery of prostate cancer stem-like cells. Cancer Res. 73, 5288-5298
17. Shodeinde, A. L., and Barton, B. E. (2012) Potential use of STAT3 inhibitors in targeted prostate cancer therapy: future prospects. Onco. Targets Ther. 5, 119-125
18. Turkson, J. (2004) STAT proteins as novel targets for cancer drug discovery. Expert Opin. Ther. Targets 8, 409-422
19. Weidler, M., Rether, J., Anke, T., and Erkel, G. (2000) Inhibition of interleukin-6 signaling by galiellalactone. FEBS Lett. 484, 1-6
20. Hellsten, R., Johansson, M., Dahlman, A., Dizeyi, N., Sterner, O., and Bjartell, A. (2008) Galiellalactone is a novel therapeutic candidate against hormonerefractory prostate cancer expressing activated Stat3. Prostate 68, 269-280
21. Hellsten, R., Johansson, M., Dahlman, A., Sterner, O., and Bjartell, A. (2011) Galiellalactone inhibits stem cell-like ALDH-positive prostate cancer cells. PLoS One 6, e22118
22. von Nussbaum, F., Hanke, R., Fahrig, T., and Benet-Buchholz, J. (2004) The high-intrinsic Diels-Alder reactivity of (δ)-galiellalactone: generating four quaternary carbon centers under mild conditions. Eur. J. Organic Chem. 2004, 2783-2790
23. Buettner, R., Corzano, R., Rashid, R., Lin, J., Senthil, M., Hedvat, M., Schroeder, A., Mao, A., Herrmann, A., Yim, J., Li, H., Yuan, Y. C., Yakushijin, K., Yakushijin, F., Vaidehi, N., Moore, R., Gugiu, G., Lee, T. D., Yip, R., Chen, Y., Jove, R., Horne, D., and Williams, J. C. (2011) Alkylation of cysteine 468 in Stat3 defines a novel site for therapeutic development. ACS Chem. Biol. 6, 432-443
24. Heidelberger, S., Zinzalla, G., Antonow, D., Essex, S., Basu, B. P., Palmer, J., Husby, J., Jackson, P. J., Rahman, K. M., Wilderspin, A. F., Zloh, M., and Thurston, D. E. (2013) Investigation of the protein alkylation sites of the STAT3:STAT3 inhibitor Stattic by mass spectrometry. Bioorg. Med. Chem. Lett. 23, 4719-4722
25. Li, L., Cheung, S. H., Evans, E. L., and Shaw, P. E. (2010) Modulation of gene expression and tumor cell growth by redox modification of STAT3. Cancer Res. 70, 8222-8232
26. Johansson, M., and Sterner, O. (2001) Synthesis of (β)- galiellalactone: absolute configuration of galiellalactone. Org. Lett. 3, 2843-2845
27. Lim, C. P., and Cao, X. (2006) Structure, function, and regulation of STAT proteins. Mol. Biosyst. 2, 536-550
28. Becker, S., Groner, B., and Müller, C. W. (1998) Three-dimensional structure of the Stat3β homodimer bound to DNA. Nature 394, 145-151
29. Schust, J., Sperl, B., Hollis, A., Mayer, T. U., and Berg, T. (2006) Stattic: a small-molecule inhibitor of STAT3 activation and dimerization. Chem. Biol. 13, 1235-1242
30. Yue, P., and Turkson, J. (2009) Targeting STAT3 in cancer: how successful are we? Expert Opin. Investig. Drugs 18, 45-56
31. Ahmad, R., Raina, D., Meyer, C., and Kufe, D. (2008) Triterpenoid CDDOmethyl ester inhibits the Janus-activated kinase-1 (JAK1) 3signal transducer and activator of transcription-3 (STAT3) pathway by direct inhibition of JAK1 and STAT3. Cancer Res. 68, 2920-2926
32. Zgheib, C., Kurdi, M., Zouein, F. A., Gunter, B. W., Stanley, B. A., Zgheib, J., Romero, D. G., King, S. B., Paolocci, N., and Booz, G. W. (2012) Acyloxy nitroso compounds inhibit LIF signaling in endothelial cells and cardiac myocytes: evidence that STAT3 signaling is redox-sensitive. PLoS One 7, e43313
33. Heinrich, P. C., Behrmann, I., Müller-Newen, G., Schaper, F., and Graeve, L. (1998) Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem. J. 334, 297-314
34. Pérez, M., Soler-Torronteras, R., Collado, J. A., Limones, C. G., Hellsten, R., Johansson, M., Sterner, O., Bjartell, A., Calzado, M. A., and Muñoz, E. (2014) The fungal metabolite galiellalactone interferes with the nuclear import of NF-κB and inhibits HIV-1 replication. Chem. Biol. Interact. 214, 69-76
35. Rudolph, K., Serwe, A., and Erkel, G. (2013) Inhibition of TGF-β signaling by the fungal lactones (S)-curvularin, dehydrocurvularin, oxacyclododecindione and galiellalactone. Cytokine 61, 285-296
36. Yang, J., Chatterjee-Kishore, M., Staugaitis, S. M., Nguyen, H., Schlessinger, K., Levy, D. E., and Stark, G. R. (2005) Novel roles of unphosphorylated STAT3 in oncogenesis and transcriptional regulation. Cancer Res. 65, 939-947